New research presented at the Alzheimer’s Association International Conference (AAIC) provided validation for BrainCheck, a digital cognitive assessment tool. Researchers from the University of Washington found that BrainCheck Assess, a 15-minute standard battery test, showed high alignment with the widely-used Montreal Cognitive Assessment (MoCA) in distinguishing between normal cognition, mild cognitive impairment, and dementia.
Unlike traditional paper-based screening tools, BrainCheck Assess is an FDA Class II medical device that can be used digitally, allowing for cognitive assessments to be conducted in-office or at home. The tool compares patient results against a normative database, offering domain-specific insights to aid in diagnosis.
Dr. Reza Ghomi, chief medical officer at BrainCheck and a neuropsychiatrist at the University of Washington, stated, “BrainCheck Assess offers accuracy on par with traditional screening tools, along with the added convenience of a device-agnostic digital test that can be taken in-office or at home, making cognitive assessments convenient for both patients and clinicians.”
A second study from the University of Washington demonstrated that BrainCheck Assess corresponds with dementia staging, and has increased accuracy when combined with the Index of Independence in Basic Activities of Daily Living (ADL). Though the tool is not intended for dementia staging, this research guides clinicians using the BrainCheck Platform in decision-making.
Additionally, researchers from the University of Pennsylvania conducted a qualitative study that identified implementation barriers and facilitators to care planning. This research further supports the need for digital and scalable cognitive care planning tools.
These studies contribute to the growing body of evidence supporting the use of digital cognitive assessment tools in clinical practice, potentially improving early detection and management of cognitive impairments.
